Ra Pharma acquired for $2.1B by Belgian firm that vows to grow in Boston

The Cambridge biotech, which is in late-stage trials of a drug to treat a rare muscle disease, has been acquired by Belgium-based UCB for $2.1 billion, immediately doubling the market value of the Cambridge firm.